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Summary
The leucine-rich-repeat receptor serine/threonine ki-
nase, BRI1, is a cell-surface receptor for brassinoster-
oids (BRs), the steroid hormones of plants, yet its ac-
tivation mechanism is unknown. Here, we report a
unique autoregulatory mechanism of BRI1 activation.
Removal of BRI1’s C terminus leads to a hypersensi-
tive receptor, indicated by suppression of dwarfism
of BR-deficient and BR-perception mutants and by
enhanced BR signaling as a result of elevated phos-
phorylation of BRI1. Several sites in the C-terminal
region can be phosphorylated in vitro, and transgenic
Arabidopsis expressing BRI1 mutated at these sites
demonstrates an essential role of phosphorylation in
BRI1 activation. BRI1 is a ligand-independent homo-
oligomer, as evidenced by the transphosphorylation
of BRI1 kinase in vitro, the dominant-negative effect
of a kinase-inactive BRI1 in transgenic Arabidopsis,
and coimmunoprecipitation experiments. Our results
support a BRI1-activation model that involves inhibi-
tion of kinase activity by its C-terminal domain, which
is relieved upon ligand binding to the extracellular
domain.
Introduction
Plasma-membrane-localized receptor kinases play
essential roles in perceiving and processing various
stimuli in both plants and animals. The Arabidopsis ge-
nome contains more than 400 genes encoding putative
receptor-like kinases (RLKs) with a variety of extracellu-
lar domains (Shiu and Bleecker, 2001b), which together
represent one of the largest gene families in Arabidop-
sis and provide a great challenge to dissect their func-
tions and regulatory mechanisms. Although these plant
RLKs are structurally similar to their animal counter-
parts, there are some major distinctions between the
two. All plant RLKs are predicted to be serine/threonine
kinases, whereas most animal receptor kinases are ty-
rosine kinases (RTKs) (Schlessinger, 2000), apart from
a notable exception, the transforming growth factor β*Correspondence: chory@salk.edu(TGFβ) receptor family (Massagué, 1998). In addition,
extracellular domains of plant RLKs are quite different
from most RTKs (Shiu and Bleecker, 2001b). Among the
plant RLKs, 214 genes belong to a super class of LRR-
RLKs that feature an extracellular leucine-rich-repeat
(LRR) domain. These LRR-RLKs have diverse biological
functions in disease resistance, growth, and develop-
ment (see reviews of Shiu and Bleecker, 2001a; Becraft,
2002; Morris and Walker, 2003; Diévart and Clark, 2004).
However, unlike many animal receptor kinases, the
knowledge of a ligand-induced activation mechanism
of the plant RLKs is lacking.
Brassinosteroid insensitive 1 (BRI1) is one of the few
plant LRR-RLKs with a known ligand and a well-defined
downstream signaling pathway. BRI1 binds brassino-
lide (BL), the most active brassinosteroid (BR), at the
cell surface via its extracellular domain (Kinoshita et al.,
2005) and regulates various aspects of plant develop-
ment, including stem elongation, pollen tube growth,
fertility, senescence, and resistance to biotic and abi-
otic stresses (Clouse et al., 1996; Mandava, 1988). So
far, all known bri1 alleles are loss-of-function mutants
resulting in extremely dwarfed plants with delayed leaf
senescence and with reduced male fertility or complete
sterility (Li and Chory, 1997; Noguchi et al., 1999). BR-
deficient mutants display similar phenotypes (Fujioka
and Yokota, 2003), indicating that BRI1 plays a key role
in BR perception.
In addition to BRI1, another LRR-RLK, BAK1, can in-
teract with BRI1 and may be involved in the early steps
of BR signaling (Nam and Li, 2002; Li et al., 2002).
Downstream of BRI1, BIN2, a glycogen synthase ki-
nase-3 family member (Li and Nam, 2002) acts as a
negative regulator by phosphorylating two nearly iden-
tical positive regulators, BES1 and BZR1, thereby
targeting them for turnover by the proteasome (Wang
et al., 2002; Yin et al., 2002; He et al., 2002; Zhao et al.,
2002). In the presence of BRs, BIN2 is inactivated by
an unknown mechanism, allowing hypophosphorylated
BES1 and BZR1 to accumulate in the nucleus where
they regulate BR-responsive gene expression (Yin et
al., 2005; He et al., 2005). BSU1, a nuclear serine/threo-
nine phosphatase, counteracts the action of BIN2 to
regulate the dephosphorylation and accumulation of
BES (Mora-García et al., 2004). Although a significant
gap in the pathway is present between BRI1 and BIN2,
the phosphorylation status and abundance of BES1/
BZR1 proteins appears to be a key downstream regula-
tory point in the pathway and can be used as a bio-
chemical measure of BRI1’s signaling output. These
findings make BRI1 an excellent system for the inves-
tigation of the regulatory mechanisms of the plant
LRR-RLKs.
Mutational analyses of BRI1 and other LRR-RLKs in-
dicate that the intracellular kinase domain is essential
for their function. BRs induce BRI1 phosphorylation in
vivo (Wang et al., 2001), but the biological relevance of
BRI1 phosphorylation and molecular mechanisms in-
volved in this process remain unknown. In addition, re-
ceptor oligomerization is a general principle for the li-
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dsurface receptor kinases (Schlessinger, 2000; Shi and
Massague, 2003), and it is likely the case for plant LRR-
lRLKs because of their single transmembrane domain
(Hubbard, 1999). In Arabidopsis, although BAK1 can in- K
dteract with BRI1 (Nam and Li, 2002; Li et al., 2002), it is
unknown whether BAK1 is involved in ligand binding or (
iwhether BRI1 homo-oligomerization or heterodimeriza-
tion is involved in ligand-regulated activation of BRI1. i
In this study, we report that BRI1 activity is directly
related to its in vivo phosphorylation and that BL is re- t
iquired for BRI1 activation in planta. The C-terminal re-
gion of BRI1’s intracellular domain plays a critical role i
rin regulating its activity in a negative manner, as evi-
denced by phenotypic analysis of transgenic Arabidop- t
Bsis with various bri1 mutations and by in vitro and in
vivo biochemical experiments. In addition, our bio- p
pchemical and genetic results strongly suggest that
BRI1 monomers interact, which is likely required for c
itransphosphorylation and activation of BRI1, and show
that BAK1 is not required for BL binding to BRI1. These t
afindings support a model whereby BRI1 activation in-
volves a series of steps: A ligand-induced conforma- r
ational change through a preformed homo-oligomer is
followed by the transphosphorylation of the kinase do- l
emain to release the autoinhibitory influence of the
C-terminal domain, which then allows further phos- c
fphorylation of BRI1 to fully activate the receptor.
f
FResults
o
tThe Juxtamembrane and C-Terminal Domains
tRegulate BRI1 Activity
aGenetic studies indicate that BRI1 kinase activity is re-
aquired for the function of BRI1 (Friedrichsen et al.,
m2000). We sought to understand the mechanism
whereby BRI1 kinase is regulated. Like most protein ki-
snases, BRI1 kinase can be phosphorylated at multiple
tsites through the intracellular-juxtamembrane (JM) do-
omain, the catalytic domain, and the C-terminal (CT) do-
amain (Oh et al., 2000; Figure 1A). Most loss-of-function
cmutations in BRI1 map to conserved regions in the ca-
etalytic domain (Friedrichsen et al., 2000), but whether
lthe JM and CT domains play regulatory roles in the acti-
vation of BRI1 kinase is unknown. To investigate the
upossible functions of these regions, we created a set
iof full-length and truncated BRI1 constructs (Figure 1A)
mwith a C-terminal FLAG epitope tag driven by the native
BRI1 promoter and introduced them into different Arab-
idopsis strains, including a BR-perception mutant, bri1-5, T
Band a BR-biosynthetic mutant, det2-1. The bri1-5 back-
ground enables us to determine which truncated recep- F
ators are functional, and the det2-1 background allows
us to assess the dependence of each receptor on li- g
tgand. As shown in Figure 1A, these constructs include
the full-length BRI1 (BRI1-FL-FLAG), BRI1 with a C-ter- a
Fminal 41 amino acid deletion (BRI1-CT-FLAG), BRI1
with a deletion of the intracellular-juxtamembrane re- b
agion (residues 815 to 882) (BRI1-JM-FLAG), the whole
intracellular domain of BRI1 (BRI1-JKC-FLAG), the in- h
ptracellular domain with the C-terminal 41 amino acids
deleted (BRI1-JK-FLAG), the intracellular domain with t
sthe intracellular JM deletion (BRI1-KC-FLAG), and thentracellular domain with both the C-terminal and JM
omains deleted (BRI1-K-FLAG).
Four constructs with only portions of the intracel-
ular domain (BRI1-JKC-FLAG, BRI1-JK-FLAG, BRI1-
C-FLAG, and BRI1-K-FLAG) did not suppress the
warf phenotype of either bri1-5 (Figure 1B) or det2-1
Figure 1C). Most likely, these proteins were mislocal-
zed or unstable; we could not detect expressed protein
n transgenic bri1-5 or det2-1 plants (data not shown).
BRI1-JM-FLAG also did not rescuebri1-5ordet2-1, al-
hough a significant amount of protein was detectable
n the transgenic lines by immunoblotting (Figure 1D),
ndicating that the JM region is required for a functional
eceptor. To determine the cellular localization of this
runcated receptor, we expressed BRI1-JM from the
RI1 promoter with a C-terminal yellow fluorescent
rotein (YFP) tag. Although some BRI1-JM-YFP fusion
rotein is localized to the cytoplasm, there is a signifi-
ant amount that localized to the cell surface, indicat-
ng that the JM domain is not essential for BRI1 to get
o the surface (Figure 1E). Moreover, an in vitro kinase
ssay of the BRI1 intracellular domain lacking the JM
egion showed slightly lower but significant amounts of
utophosphorylation in vitro (X.W. and J.C., unpub-
ished data), suggesting that the JM domain is not
ssential for in vitro kinase activity. These results indi-
ate that BRI1 kinase may require the JM region to be
ully activated in vivo or that the JM domain is required
or recruiting BRI1’s substrates. As expected, BRI1-
L-FLAG completely suppressed the dwarf phenotype
f bri1-5 (Figure 1B), but it also significantly suppressed
he det2-1 phenotype (Figures 1C and 2A). An explana-
ion for this is that levels of BR produced by det2-1 are
bout 10% of levels produced by wild-type (Fujioka et
l., 1997), and plants with overexpressed receptors
ay become more sensitive to BL.
Expression of BRI1-CT-FLAG showed the most
triking phenotype. BRI1-CT-FLAG completely or par-
ially suppressed the dwarf phenotype of either bri1-5
r det2-1 to a greater extent than BRI1-FL-FLAG did,
s measured by the length of hypocotyls (longer hypo-
otyls equal more BR response) (Figures 1B and 1C),
ven though the level of BRI1-CT-FLAG protein was
ower than that of BRI1-FL-FLAG (Figure 1D). BRI1-
CT-YFP was properly localized to the cell surface (Fig-
re 1F). These results suggest that the BRI1-DCT-FLAG
s a gain-of-function mutation of BRI1 and results in a
ore active receptor.
he C-Terminal Domain Negatively Regulates
RI1 Function
or detailed phenotypic analyses of BRI1-CT-FLAG
nd BRI1-FL-FLAG transgenic Arabidopsis, two trans-
enic lines for each construct were assayed quantita-
ively. Hypocotyl length was used as an output of the
ctivity of each receptor. In the light, both BRI1-
L-FLAG and BRI1-CT-FLAG completely rescued the
ri1-5 mutant and showed a hypermorphic phenotype,
nd, likewise, BRI1-CT-FLAG bri1-5 lines had longer
ypocotyls than BRI1-FL-FLAG bri1-5 lines at similar
rotein levels (Figure 2A). In the det2-1 background,
ransgenic Arabidopsis expressing BRI1-FL-FLAG had
ignificantly longer hypocotyls than det2-1 (Figure 2B).
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857Figure 1. The C-Terminal and Intracellular JM Domains of BRI1 Play Negative and Positive Roles in BRI1 Function, Respectively.
(A) Schematic diagram of full-length and truncated BRI1 constructs. The following abbreviations are used: SP, signal peptide; ED, extracellular
domain; TM, transmembrane domain, JM, intracellular-juxtamembrane domain; KD, kinase catalytic domain; and CT, C terminus. The amino
acid positions at the N- and C-terminal end of the JM and CT domain are indicated. The constructs were driven by a native BRI1 promoter
with a Rubisco small subunit (rbsc) terminator, and proteins were fused with a C-terminal FLAG epitope tag.
(B) Seedling phenotypes of transgenic bri1-5 harboring various BRI1 constructs. Seedlings are from a typical transgenic line of each construct.
FL, CT, JM, JKC, JK, KC, and K stand for transgenic bri1-5 containing FLAG tagged BRI1 variants shown in (A).
(C) Seedling phenotypes of transgenic det2-1 transformed with BRI1 constructs. Seedlings are from a typical transgenic line for each con-
struct. FL, CT, JM, JKC, JK, KC, and K stand for transgenic det2-1 containing FLAG- tagged BRI1 variants shown in (A).
(D) Transgene expression of BRI1-FL-FLAG, BRI1-CT-FLAG, and BRI1-JM-FLAG in det2-1, detected by immunoblotting with anti-FLAG an-
tibodies.
(E) Plasma-membrane localization of BRI1-JM-YFP.
(F) Plasma-membrane localization of BRI1-CT-YFP.The BRI1-CT-FLAG det2-1 lines resulted in long hypo-
cotyls (Figures 2B and 2C), which were even longer
than those resulting from the wild-type Col-0, indicating
that BRI1-CT-FLAG is a more active receptor than the
wild-type and that the CT domain somehow inhibits
BRI1 function. In addition to elongated hypocotyls, the
transgenic plants also showed expanded leaves, elon-
gated petioles, and increased fertility compared to their
host mutant plants (data not shown), which supports
the interpretation that BRI1-CT-FLAG plants are hy-
persensitive to BRs.
To further assess ligand-dependence of these trans-
genic plants, we measured their response to an inhibi-
tor of BR biosynthesis, BRZ220 (Sekimata et al., 2002).
We observed that hypocotyl elongation of det2-1,
transgenic det2-1 with BRI1-FL-FLAG, and the wild-
type was strongly inhibited by low levels of BRZ220,
whereas transgenic det2-1 with BRI1-CT-FLAG was
more resistant to this chemical (Figure 2D). With 2 M
BRZ in the growth medium, we observed that hypocotyl
elongation of wild-type and det2-1 was dramatically re-
duced, by 59% and 60%, respectively, and that the hy-
pocotyl length of transgenic det2-1 with BRI1-FL-FLAG
was also greatly reduced (by 75%). However, the hypo-
cotyl length of transgenic det2-1 with BRI1-CT-FLAG
was only slightly reduced (by about 14%), and their hy-pocotyls were even longer than that of BRI1-FL-FLAG
det2-1 lines without BRZ (Figure 2D). These results sug-
gest that hypocotyl elongation of BRI1-FL-FLAG trans-
genic lines still largely relied on BL; in contrast, BRI1-
CT-FLAG transgenic plants were less dependent on BL.
BRI1 Lacking the C-Terminal Domain Has
Enhanced BR Downstream Signaling
We then asked whether the enhanced hypocotyl elon-
gation caused by BRI1-CT-FLAG expression was due
to elevated BRI1 signaling. Previous studies have
shown that dephosphorylated BES1 accumulates in the
nucleus in response to BL (Yin et al., 2002; Mora-García
et al., 2004). Therefore, we quantified the dephosphory-
lated BES1 in these transgenic det2-1 seedlings by im-
munoblot analysis with anti-BES1 antibodies. As shown
in Figure 2E, a greatly elevated accumulation of dephos-
phorylated BES1 was observed in the BRI1-FL-FLAG
and BRI1-CT-FLAG det2-1 lines compared to det2-1. In
the absence of BL, there was significantly (p < 0.05)
more of the dephosphorylated BES1 in BRI1-CT-FLAG
det2-1 lines than in the BRI1-FL-FLAG det2-1 lines.
Treatment with 0.1 M BL for one hour enhanced the
accumulation of dephosphorylated BES1 in all sam-
ples; the transgenic BRI1-CT-FLAG det2-1 accumu-
lated a significantly (p < 0.05) larger amount of de-
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858Figure 2. BRI1-CT Is a Hyperactive Form
of BRI1
(A) Hypocotyl length of light-grown Ws-2,
bri1-5, and transgenic bri1-5 seedlings with
BRI1-FL and BRI1-CT. Error bars indicate
standard error. Immunoblots with anti-FLAG
(shown below the histograms) show the re-
ceptor level. The Ponceau-S stained Ru-
bisco large subunit serves as a loading
control.
(B) Hypocotyl length of light-grown Col-0,
det2-1, and transgenic det2-1 seedlings ex-
pressing BRI1-FL and BRI1-CT. Error bars
indicate standard error. Immunoblots with
anti-FLAG (shown below the histograms)
show the receptor level. Rubisco large sub-
unit serves as a loading control.
(C) Representative light-grown seedlings of
Col-0, det2-1, and transgenic det2-1 with
BRI1-FL and BRI1-CT.
(D) Transgenic det2-1 with BRI1-CT is more
resistant to BRZ220 than that with BRI1-FL.
Seedlings were grown for 3 days in the dark.
Error bars indicate standard error.
(E) Expression of BRI1-CT enhances BRI1
downstream signaling. The amount of de-
phosphorylated BES1 from short-day-grown
transgenic det2-1 plants was quantified via
immunoblotting and the Odyssey Infrared
Imaging system (LI-COR Biosciences); “−”
and “+” stand for samples untreated and treated with 0.1 M BL for 60 min, respectively. The amount of dephosphorylated BES1 in each
membrane was normalized with the mean of all samples on the same membrane. Three independent measurements were conducted. Error
bars indicate standard error. T test was performed to determine the significance of comparisons.phosphorylated BES1 than did those expressing BRI1- 0
wFL-FLAG (Figure 2E). These data demonstrate that
BRI1 lacking the CT domain enhanced its downstream- B
vsignaling output.
t
oDeletion of the C-Terminal Domain Enhances
BRI1 Kinase Activity f
iThere are several possible mechanisms by which the
CT domain could negatively regulate BRI1 activity: It l
may directly inhibit BRI1’s kinase activity and/or sub-
strate access; it may recruit other proteins that inhibit T
PBRI1’s kinase activity; and/or it may recruit inhibitory
proteins that block substrate binding. To distinguish P
pbetween these possibilities, we first compared the in
vitro kinase activity of the BRI1 intracellular domain p
Twith (JKC) or without (JK) the CT domain expressed as
an N-terminal Glutathionine-S-Transferase (GST) fusion. o
rOur results revealed that the GST-JK had significantly
higher (2-fold) autophosphorylation activity than the GST- m
(JKC had (Figure 3A), suggesting that the CT domain
could directly inhibit BRI1 kinase activity. b
tTo determine whether BRI1-CT-FLAG had elevated
kinase activity in planta, we fed seedlings radioactive b
porthophosphate (32PO4) and monitored phosphoryla-
tion of BRI1 expressed with a C-terminal FLAG tag. a
4Autoradiography and immunoblot analysis of immuno-
precipitated BRI1-FLAG from transgenic plants demon- s
ustrated that BL induced BRI1 phosphorylation, as ex-
pected, and that BRI1-CT-FLAG was phosphorylated p
tto a greater extent than BRI1-FL-FLAG. As shown in
Figure 3B, without BL treatment the 32P radioactive sig- d
tnals in both BRI1-FL-FLAG and BRI1-CT-FLAG trans-
genic det2-1 plants were low (0.30 ± 0.09 for FL versus t.56 ± 0.19 for CT; p = 0.087). After a 10 min treatment
ith BL, the radioactive signal was enhanced in both
RI1-FL-FLAG and BRI1-CT-FLAG (0.82 ± 0.21 for FL
ersus 1.27 ± 0.14 for CT; p = 0.100), and a longer
reatment (30 min) with BL further increased the level
f 32P incorporation into both forms of BRI1 (0.98 ± 0.11
or FL versus 2.08 ± 0.37 for CT; p = 0.025). Thus, BRI1
n vivo phosphorylation is tightly regulated by both its
igand and its own structure.
he C-Terminal Domain of BRI1 Has Multiple
hosphorylation Sites
hosphorylation is one of the most prevalent forms of
rotein modification and is often a key regulatory com-
onent in signal-transduction cascades (Hunter, 2000).
he CT region of BRI1 contains six serine and two thre-
nine residues (Figure 4A). To test whether any of these
esidues can be phosphorylated, we synthesized a 41-
er peptide (CT-41: 1156–1196) and a 25-mer peptide
CT-25: 1172–1196), which were in vitro phosphorylated
y BRI1 kinase. Phosphoamino acid analysis indicated
hat both Ser and Thr residues were phosphorylated in
oth peptides (Figure 4B). T1180 is one residue that is
hosphorylated because it is the only Thr in CT-25. We
lso compared tryptic phosphopeptide digests of CT-
1, GST-JKC, and GST-JK by separation in two dimen-
ions on thin-layer cellulose (TLC) plates. As shown in Fig-
re 4C, although the CT-41 peptide contains only two
redicted Ser/Thr-containing tryptic phosphopeptides,
ryptic digestion of this peptide generated five well-
efined radioactive spots, which are most likely indica-
ive of peptides carrying multiple phosphates or of par-
ially-cleaved peptides. Consistent with this, most of
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859Figure 3. BRI1-CT Has Higher Phosphorylation Activity, Both In
Vitro and In Planta, Than Full-Length BRI1
(A) BRI1 intracellular domain with a C-terminal deletion (GST-JK)
has higher in vitro autophosphorylation activity than the entire BRI1
intracellular domain (GST-JKC). The histograms show the activity
of GST-JK relative to that of GST-JKC. The left panel is an autora-
diogram of the in vitro phosphorylation reaction, and the right panel
is the Coomassie-blue-stained gel. The activity of GST-JKC was
defined as “1.” Three independent measurements were conducted.
Error bars indicate standard error.
(B) BRI1-CT has higher in vivo phosphorylation activity than BRI1-
FL. BRI1 was immunoprecipitated from extracts of 32P-labeled
seedlings, and gel electrophoresis and PhosphorImager analysis
followed (see Experimental Procedures). The time (min) of BL treat-
ment for each sample is indicated. Two independent measure-
ments for each of the two independent in vivo labeling studies were
conducted. Error bars indicate standard error. T test was per-
formed to determine the significant level of comparisons.these spots (circled in Figure 4C) are present in the
GST-JKC map but absent in the GST-JK map, confirm-
ing that these residues are phosphorylated in the CT
domain. The one significant spot (squared in Figure 4C)
present in the CT map but absent in the GST-JKC map
may represent the N-terminal phosphopeptide with an
additional uncleaved lysine residue (KEIQAGSGIDSQ-
STI); trypsin is known to be a poor aminopeptidase, and
the predicted mobility of this phosphopeptide (Gene-
stream) supports this explanation. Analysis of phos-
phopeptide maps of mixtures of the digests of GST-
JKC and CT-41 (JKC+CT) or GST-JK and CT-41 (JK+CT)
samples was also consistent with this interpretation
(Figure 4C).
To further investigate the phosphorylation sites in the
CT region, we constructed BRI1 mutations by substitut-
ing certain or all of the Ser/Thr residues with the acidic
amino acid Asp, which, in some cases, can mimic the
phosphorylation of Ser/Thr. The intracellular domains of
these three mutants (N5D, C3D, and All-D; see Figure
4D) were expressed as GST fusion proteins and auto-
phosphorylated in vitro. Analysis of phosphopeptide
maps of samples doubly digested with trypsin and
thermolysin further suggested that several Ser and Thr
were phosphorylated in the CT region and that S1162
is likely to be one phosphorylation site because all mu-
tants containing S1162D lost one significant phospho-
peptide in comparison to wild-type BRI1 kinase (seeFigure S1 in the Supplemental Data available with this
article online). Taken together, our data suggest that the
CT domain of BRI1 likely contains at least two phos-
phorylation sites, S1162 and T1180, with other as yet
undetermined sites. Additional in vitro phosphorylation
sites are located in the catalytic domain and the juxta-
membrane domain (data not shown), accounting for the
complexity of the peptide maps.
Phosphorylation of C-Terminal Serine/Threonine
Residues Plays an Important Role in BRI1 Activation
To determine the regulatory role of the potential phos-
phorylation sites of the C-terminal region on BRI1 func-
tion in vitro, we measured the kinase activity of BRI1
containing three different combinations of point muta-
tions in the CT region. These assays indicated that the
BRI1 mutant with five Ser/Thr mutated to Asp proximal
to the catalytic domain (N5D) had slightly elevated au-
tophosphorylation, whereas the BRI1 mutant with all
eight Ser/Thr mutated to Asp (All-D) and the C3D (with
the S1162D mutation plus the three Ser/Thr to Asp in
the distal CT region) significantly increased kinase ac-
tivity (Figure 4E). These data suggest that the phos-
phorylated residues (most likely including T1180) in the
distal C-terminal region are involved in the direct inhibi-
tion of kinase activity.
To assess the function of these bri1 mutants in
planta, we transformed the three full-length BRI1 vari-
ants, N5D, C3D, and All-D, which were expressed with
a C-terminal FLAG tag under the control of the native
BRI1 promoter, into the BR-deficient mutant, det2-1. As
an output of BRI1 signaling, hypocotyl lengths of the
progeny of transformed plants (T2) were measured. The
expression level of BRI1 in the transgenic lines was de-
termined with anti-BRI1 antibody (Figure 4F). In agree-
ment with the in vitro kinase assays, the BRI1-C3D-
FLAG and BRI1-All-D-FLAG, in comparison to wild-type
BRI1, greatly enhanced hypocotyl elongation. More-
over, the BRI1-N5D-FLAG, in comparison to wild-type
BRI1, also significantly enhanced hypocotyl elongation
(Figure 4F). These data suggest that phosphorylation of
some residues in the CT domain releases its inhibitory
effect on BRI1 activity in vitro and in planta.
BRI1 Phosphorylation Is Intermolecular
The fact that the CT-41 peptide was phosphorylated by
BRI1 in vitro suggests that transphosphorylation be-
tween BRI1 molecules is possible. To test this, we incu-
bated GST-JKC and GST-JK together in a kinase assay,
and we observed that the phosphorylation of both pro-
teins was enhanced as compared to each kinase alone
(Figure 5A). To test whether a kinase-inactive BRI1 can
be phosphorylated by BRI1 kinase, we constructed a
kinase-inactive BRI1-JKC (K911E), called mJKC (Oh et
al., 2000; Li et al., 2002), and incubated it with GST-
JKC. We found that mJKC completely lacked kinase
activity and that the wild-type BRI1 kinase could effi-
ciently transphosphorylate mJKC (Figure 5B).
BRI1 Interacts with Itself In Planta
If homo-oligomerization is required for the activation of
BRI1 in vivo, it is reasonable to expect that expression
of a kinase-inactive BRI1 in plants will negatively affect
Developmental Cell
860Figure 4. Phosphorylation of Multiple Resi-
dues in the CT Domain of BRI1 Plays an
Essential Role in Regulating BRI1 Function
(A) The amino acid sequence of BRI1’s CT
domain. The S/T (Ser/Thr) residues are
shown in bold. Arrows shown below the se-
quence indicate predicted trypsin cleavage
sites, and arrows shown above the se-
quence indicate the amino acid position.
(B) Serine and threonine residues of the CT
peptides can be phosphorylated by BRI1 ki-
nase. The CT-41 and CT-25 peptides phos-
phorylated by BRI1 kinase were purified on
a 16% Tricine SDS-PAGE gel and acid hy-
drolyzed, and the hydrolysates were sepa-
rated by electrophoresis on a TLC plate.
(C) There are multiple phosphorylation sites
in the CT region. Phosphopeptide mapping
was conducted for the CT-41 peptide (CT);
for GST-JKC (JKC); for a mix of both GST-
JKC and CT-41 (JKC + CT); for GST-JK (JK);
and for a mix of GST-JK and CT-41 (JK + CT).
These recombinant proteins were autophos-
phorylated and the CT peptide was phos-
phorylated by GST-JKC; labeled proteins
were trypsin digested, and the digests were
separated on TLC plates (see Experimental
Procedures). The sample origins are indi-
cated by “+,” and electrophoresis was to-
ward the cathode. Circled spots indicate
phosphopeptides consistently present in the
CT-41 peptide and the GST-JKC maps but
absent in those of GST-JK. The squared spot
indicates a phosphopeptide only present in
the digests of the synthetic peptide.
(D) BRI1 mutant constructs with substitutions of certain S/T (Ser/Thr) to D (Asp) in the CT region.
(E) In vitro autophosphorylation assays of BRI1 mutants. The autophosphorylated kinases were separated on a SDS-PAGE gel and transferred
to PVDF membrane (Millipore). Protein content was determined by immunoblotting with anti-GST antibody via the Odyssey Infrared Imaging
system (LI-COR Biosciences), and radioactive signals were quantified with a PhosphorImager on the same membrane. The activity of wild-
type kinase (cpm/protein) was defined as “1.” Error bars indicate standard error.
(F) Hypocotyl lengths of transgenic det2-1 (T2) with different forms of BRI1 grown in short-day conditions. The expression level of each BRI1
construct was determined by immunoblotting with anti-BRI1 antibodies. The Ponceau-S stained Rubisco large subunit serves as a loading
control. Error bars are standard error.the function of wild-type BRI1. To test this prediction, w
wwe expressed a full-length kinase-inactive BRI1 (K911E)
with a C-terminal FLAG tag in bri1-5 and wild-type n
aWs-2 backgrounds driven by a BRI1 promoter. In the
bri1-5 background, all T1 seedlings (more than 40) dis- a
pplayed a severe bri1 phenotype, as shown in Figure 5C,
with dwarf stature, dark green leaves, and complete f
sterility. A dominant-negative effect was also observed
in the wild-type Ws-2 background (Figure 5D). Because B
Bsome lines with high expression levels of kinase-
inactive BRI1 were sterile, later generations (T3) of i
msome lines with only low or moderate expression levels
of transgenes were established. Phenotypic analysis of p
mlight-grown seedlings indicated that the degree of inhi-
bition of endogenous BRI1 function was correlated with E
cthe expression level of the transgenes, with higher ex-
pression levels causing smaller and shorter seedlings t
a(Figures 5D and 5E). To test whether this effect was
caused by ligand titration for endogenous BRI1, we b
cmeasured the response of the transgenic plants to
exogenously applied BL. In these experiments, the a
ttransgenic lines were less sensitive to BL treatment
than the wild-type Ws-2 were (Figure 5F), and line 9-3, which expresses a higher level of mutated BRI1 protein,
as the least sensitive to BL, suggesting that the domi-
ant-negative effect is not caused by the titration of
vailable BL by the mutant BRI1. Thus, expression of
kinase-inactive BRI1 resulted in a dominant-negative
henotype, probably by interrupting endogenous BRI1
unction.
To further determine a physical interaction between
RI1 molecules in vivo and whether this interaction was
L-dependent, we created transgenic plants express-
ng both BRI1-FLAG and BRI1-CFP in the BR-deficient
utant background, det2-1, and tested for coimmuno-
recipitation of the two tagged forms of BRI1. Total
embrane proteins were isolated, as described in the
xperimental Procedures, from transgenic seedlings
ontaining both BRI1-FLAG and BRI1-CFP, and the
ransgenic plants containing only BRI1-GFP were used
s a control. To determine a possible effect of ligand
inding on BRI1 oligomerization, we treated one set of
otransformed seedlings with 1 M of BL, which was
lso present in all buffers during the coimmunoprecipi-
ation process. As shown in Figure 5G, BRI1 interacted
ith itself in plants, both in the presence and absence
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(A) Enhancement of phosphorylation in the presence of both GST-
JKC and GST-JK.
(B) Transphosphorylation of a kinase-inactive BRI1, mJKC (K911E),
by GST-JKC in vitro.
(C) Dominant-negative effect of kinase-inactive BRI1 in transgenic
bri1-5. The phenotypes of light-grown seedlings of bri1-5 and
transgenic bri1-5 (T1) harboring a full-length kinase-inactive BRI1
(mBRI1), pBRI1::mBRI1-FLAG are shown. The anti-FLAG immu-
noblot shows the accumulation of mBRI1-FLAG.
(D) Dominant-negative effect of kinase-inactive BRI1 in transgenic
Ws-2. The seedlings were grown in short-days. Line 2-1 and line
9-3 are two transgenic lines (T3) expressing mBRI1-FLAG.
(E) The anti-FLAG immunoblot shows the levels of mBRI1-FLAG
expression in the two lines, and the anti-BRI1 immunoblot shows
the level of endogenous BRI1 in the Ws-2 parental line in compari-
son to the combined level of endogenous and mBRI1-FLAG in the
transgenic lines. The Ponceau-S stained Rubisco serves as a load-
ing control.
(F) Transgenic Ws-2 with mBRI1-FLAG was less sensitive to exoge-
nous BL than Ws-2. Each measurement is the average (mean ±
standard error) of 15–20 4-day light-grown seedlings.
(G) BL-independent interaction of BRI1-FLAG and BRI1-CFP in
vivo. Total membrane proteins and proteins immunoprecipitated
from the membrane fraction were separated on a 4%–20% SDS-
PAGE gel. The anti-FLAG immunoblot in the bottom panel shows
the level of BRI1-FLAG in the anti-FLAG immunoprecipitates and
in the membrane fractions. The anti-GFP immunoblot in the top
panel shows the level of BRI1-CFP in the anti-FLAG immunopreci-
pitates and in the membrane fractions obtained by probing a dupli-
cate nitrocellulose membrane. Lanes 1 and 4 are from transgenic
Col-0 overexpressing BRI1-GFP alone. Lanes 2, 3, 5, and 6 are
from transgenic det2-1 seedlings expressing both BRI1-CFP and
BRI1-FLAG.of ligand, and BL treatment appeared to increase the
extent of coimmunoprecipitation, suggesting that BL
binding may also stabilize the preformed BRI1 dimer.Discussion
In this study, we provide evidence that BRI1 activity is
negatively regulated by its C-terminal domain. The in
vivo 32P-labeling experiments with transgenic plants in
a BR-deficient mutant background confirmed that
when BL concentrations are low, the BRI1 kinase is
kept at a low basal state and ligand is required for its
rapid phosphorylation in planta. Our biochemical and
genetic analyses with truncated and mutated BRI1 re-
ceptors strongly support the idea that the CT domain
negatively regulates BRI1 function by directly inhibiting
the kinase activity. Removal of the C-terminal domain
leads to a more active receptor, indicated by longer hy-
pocotyls in transgenic plants, by a higher in vitro and
in vivo phosphorylation activity, and by enhanced BR
downstream signaling. In the BR-biosynthetic mutant,
det2-1, the BRI1-CT-FLAG exhibited greatly reduced
dependence on BL. Although we cannot completely ex-
clude the possibility of the CT domain also binding
other unknown inhibitory proteins, our data favor the
possibility of direct inhibition. The CT domain of BRI1
likely specifically inhibits BRI1 kinase because a chi-
meric receptor consisting of CLV1 with the substitution
of its CT domain by that of BRI1 behaves normally (Dié-
vart et al., 2003).
Phosphorylation of the CT domain plays a critical role
in releasing its inhibition on BRI1 function. Using syn-
thetic peptides and phosphopeptide mapping, we
found that multiple phosphorylation sites exist in the
C-terminal tail, including two specific sites S1162 and
T1180. A previous study also suggested that there are
at least two in vitro phosphorylation sites in the CT do-
main of BRI1, although neither of these sites was
mapped and the biological significance of the phos-
phorylations were not explored (Oh et al., 2000). Substi-
tutions of all or some of the CT domain Ser/Thr with
Asp, which may mimic phosphorylation of the substi-
tuted residues, led to more-active receptors in plants,
indicating that the CT-domain conformational changes
caused by either mutagenesis or phosphorylation of
these potential phosphorylation sites play an important
role in BRI1 function. Recently, structural and biochem-
ical studies on some receptor tyrosine kinases, such as
Tie2 and PDGFR, indicate that the C-terminal tail plays
a negative role in tyrosine kinase activation (Shewchuk
et al., 2000; Niu et al., 2002; Chiara et al., 2004). How-
ever, due to the lack of structural knowledge of any
plant RLKs, it is too early to determine how such phos-
phorylation influences a conformational change of the
CT region and the catalytic domain of BRI1.
Besides the CT domain, other cis-regions of BRI1
may also play regulatory roles in BRI1 activation. In-
deed, although the CT deletion greatly enhanced BRI1
in vivo phosphorylation, the phosphorylation of BRI1-
CT-FLAG can be further induced by BL treatment, in-
dicating that phosphorylation of other domains is also
involved in full activation of BRI1. The release of CT
autoinhibition might allow the full activation to proceed
more efficiently. One such domain is likely to be amino
acids in the activation loop (Huse and Kuriyan, 2002),
which are phosphorylated in vitro (X.W., unpublished
data; Oh et al., 2000). In addition, the JM domain seems
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dof this domain leads to a nonfunctional receptor. Re-
cent studies on animal receptor kinases also suggest a i
icritical role of JM regions of certain receptor kinases in
their activation (Hubbard, 2002; Hubbard, 2004). Phos- i
sphopeptide mapping with BRI1 kinase lacking the JM
domain demonstrated that there are several phosphor- o
Fylation sites in the JM (X.W., unpublished data; Oh et
al., 2000). We currently do not know how the JM do- b
bmain of BRI1 regulates its activation, but mutational
analysis of BRI1 at the in vitro phosphorylation sites in e
mthis region may provide a clue.
Here, we present several lines of evidence suggest- t
Bing that BRI1 homo-oligomerization is involved in the
activation of BRI1. First, trans-phosphorylation be-
mtween BRI1 molecules was observed in vitro on the
basis of the fact that a kinase-inactive BRI1 was phos- t
iphorylated by a wild-type BRI1 kinase. Second, in
transgenic Arabidopsis, the kinase-inactive BRI1 can t
Cinhibit endogenous BRI1 activity, resulting in a more se-
vere phenotype in bri1-5 and a semidwarf phenotype in o
kthe wild-type background. Third, a physical interaction
between BRI1-CFP and BRI1-FLAG was detected in C
kvivo by coimmunoprecipitation. Independent evidence
for BRI1 homodimerization was also recently reported B
sby Russinova et al. (2004), who detected an interaction
between BRI1-CFP and BRI1-YFP in living protoplasts t
tby measuring fluorescence resonance energy transfer
(FRET). Because an interaction between BRI1 kinase b
sdomains was not detected in a yeast two-hybrid assay
(X. W. and J. C., unpublished), it is likely that a BRI1/ i
tBRI1 interaction is preferentially mediated by the extra-
cellular and/or transmembrane domains. That the ex- (
mtracellular domain is involved in interactions between
LRR-RLKs and their partners was also suggested by T
Tstudies on other LRR-RLKs (Shpak et al., 2003; Diévart
et al., 2003). i
bBRI1 and BAK1 may form a multimeric complex
through their intracellular domains to transduce the BR i
Tsignal. BAK1 was identified as a BRI1-associated ki-Figure 6. A Model for BRI1 Activation
In the absence of BRs, BRI1 kinase is in a
low basal activity state, in which BRI1 kinase
is hypophosphorylated and kept in an au-
toinhibitory conformation by the CT domain,
either in trans or cis. BL binding to the island
domain of BRI1 induces a conformational
change between the kinase domain (green)
through the JM domain (yellow), leading to
phosphorylation (star) of residues in the CT
domain (red); this phosphorylation could fa-
cilitate the release of its autoinhibition and
allow further autophosphorylation, thus cre-
ating a fully activated receptor. Following the
phosphorylation and activation of BRI1,
BAK1 and BRI1 likely form a multimeric com-
plex through their intracellular domains to
transduce the BR signal.ase through interactions between their intracellular
omains (Nam and Li, 2002; Li et al., 2002), and the
nteraction between wild-type BRI1 and BAK1 kinases
s significantly stronger than that between their kinase-
nactive mutants (Li et al., 2002). However, overexpres-
ion of BAK1 did not enhance the BL binding activity
f either endogenous BRI1 or overexpressed BRI1 (see
igure S2), and BL binding to BRI1 is not affected in a
ak1 null mutant (Kinoshita et al., 2005). Therefore, BL
inding to the extracellular domain of BRI1 (Kinoshita
t al., 2005) could activate BRI1 by inducing a confor-
ational change of the preformed homodimer, and then
he activated BRI1 could facilitate an interaction with
AK1 via the kinase domain.
These findings and previous information lead to a
odel for BRI1’s activation mechanism (Figure 6). In
he absence of ligand, BRI1 is present as a preformed
nactive homo-oligomer, and its kinase activity is main-
ained at a basal level via trans- or cis-repression of its
T domain. Steroid binding to the extracellular domain
f BRI1 induces a conformational change between the
inase domain and allows trans-phosphorylation of the
T region in the dimer, which likely enhances BRI1’s
inase activity and promotes further phosphorylation of
RI1, thereby providing binding sites for its substrates,
uch as BAK1 and TTL (Nam and Li, 2004). Although
he CT tail could inhibit its kinase in cis-repression, the
rans-repression mechanism may be more attractive
ecause trans binding via the C-terminal tails would
tabilize the preformed dimer; this potential mechanism
s similar to what has been proposed by a computa-
ional analysis of epidermal growth-factor receptor
EGFR) (Landau et al., 2004). A major divergence of the
odel proposed for BRI1 from the TGFβ receptor Ser/
hr kinase in metazoans is that the kinase domain of
βRII is constitutively phosphorylated in a ligand-
ndependent manner (Wrana et al., 1994), and ligand
inding to both TβRII and TβRI primarily induces their
nteraction, phosphorylation, and activation of TβRI by
βRII (Massagué, 1998). In contrast, BRI1 cannot be
Activation Mechanism of BRI1
863efficiently phosphorylated and activated without BL
binding.
The plant steroid hormone receptor BRI1 is an excel-
lent system for gaining significant insight into the li-
gand-dependent activation mechanisms of the plant
LRR-RLKs and raises questions for future investigation.
Among the plant LRR-RLKs, the CT and JM domains
are more diverse than the kinase catalytic domains,
suggesting that these regions may play regulatory roles
in activation and in determining signal specificity as
well. A recent phosphoproteomics analysis of Arabi-
dopsis plasma-membrane proteins suggests that phos-
phorylation in the CT and JM region of many RLKs is a
common feature (Nuhse et al., 2004). Our data provide
direct evidence that phosphorylation in the CT domain
of BRI1 plays an important regulatory role in its activa-
tion. Determining the three-dimensional (3D) structure
of BRI1 kinase and its various mutant forms will be re-
quired to fully appreciate the activation mechanism for
this large LRR-RLK gene family.
Experimental Procedures
Plant Materials and Growth Conditions
Columbia (Col-0) and Wassilewskiji (Ws-2) ecotypes, BR-percep-
tion mutant bri1-5 (in the Ws-2 background), and BR-biosynthetic
mutant, det2-1 (in the Col-0 background), were used. Seeds were
sterilized by 10–15 min treatment in 70% (v/v) ethanol followed by
a 10 min wash with 95% (v/v) ethanol. Phenotypic analyses of all
transgenic lines and controls were conducted on plates with 1/2
MS (Gibco) and 0.8% phytagar (Gibco), with the addition of 30 l/
ml Kanamycin for selecting transgenic plants. Plants were grown
at 22°C under white light (16-hr-light/8-hr-dark cycles for long-day
treatment or 8-hr-light/16-hr-dark cycles for short-day treatment) or
continuous dark.
Generation of Transgenic Plants and Determination
of Protein Localization
Full-length and truncated BRI1 were amplified by PCR from the
Col-0 BRI1 cDNA via Pfu DNA polymerase (Stratagene) and were
cloned into the binary vector pCHF3 that contains a BRI1 promoter
(Friedrichsen et al., 2000), a C-terminal FLAG tag (DYKDDDDKVKL)
fusion, and the Rubisco small subunit (rbcS) terminator. These con-
structs were transformed into bri1-5 and/or det2-1. Full-length ki-
nase-inactive BRI1 (mBRI1) with the K911E mutation was cloned
into the pCHF3 vector with a C-terminal FLAG tag or into the
pCHF1 vector with a C-terminal cyan fluorescent protein (CFP) tag.
All constructs were confirmed by sequencing. Similarly, BRI1-JM
and BRI1-CT with C-terminal YFP fusions were constructed and
transformed into Col-0 or Ws-2 plants, and their subcellular local-
ization was visualized and photographed with a Delta vision decon-
volution fluorescence microscope.
In Vitro Kinase Assay
The full intracellular domain of BRI1 (JKC) and intracellular domain
with CT deletion (JK) were cloned into the pET42a vector (Nova-
gen), resulting in an N-terminal GST fusion protein. Proteins were
expressed in BL21 (DE3) Codon plus RIL (Stratagene) and purified
with glutathione agarose beads (Sigma). The kinase-inactive GST-
BRI1 kinase (K911E) fusion was created by PCR-based mutagene-
sis, and once expressed, the GST tag was cleaved with factor Xa
(New England Biolabs). Each reaction contained 50 mM HEPES [pH
7.4], 10 mM MgCl2, 10 mM MnCl2, 1 mM DTT, 10 M ATP, 1 l (10
Ci) [γ-32P] ATP, 2 g of each protein, and double deionized H2O in
a final volume of 24 l. Reactions were terminated by the addition
of 8 l of 4× SDS loading buffer. Samples were separated on a
4%–20% Tris-Glycine SDS-PAGE gel (Invitrogen), which was then
stained, destained, dried, and autoradiographed.Protein Extraction from Plants for Immunoblot Analysis
Plant tissues were ground to fine powder in liquid nitrogen. Total
protein was extracted with 2× SDS buffer (1l/mg), separated on a
4%–20% Novex Tris-Glycine SDS-PAGE gel (Invitrogen), and trans-
ferred to a nitrocellulose membrane (Bio-Rad). Monoclonal anti-
FLAG antibody (Sigma) and goat anti-mouse HRP-conjugated se-
condary antibody (Bio-Rad) were used to detect FLAG fusion pro-
teins in immunoblots. Polyclonal anti-BES1 antibody (Mora-García
et al., 2004) and donkey anti-mouse IRDye 800-conjugated second-
ary antibody (Rockland Immunochemicals) were used to quantify
BES1, and the resulting signals were quantified with the Odyssey
Infrared Imaging system (LI-COR Biosciences). Multiclonal anti-
GFP antibody (Molecular Probes) and goat anti-rabbit HRP-conju-
gated secondary antibody (Bio-Rad) were used to detect green flu-
orescent protein (GFP)- or CFP-tagged proteins in immunoblots.
Signals were detected by incubating the membrane with Super Sig-
nal West Pico Chemiluminescent solution (Pierce) and exposing
them to X-ray film (Kodak).
In Vivo 32P Labeling and Immunoprecipitation of FLAG
Fusion Proteins
Light-grown seedlings were starved in H2O containing 1 M
BRZ220 for 24 hr and were incubated in 3 ml H2O containing 1 M
BRZ220 and 0.5 mCi of 32PO4 overnight. Plant tissues were washed
five to six times with water, frozen, and ground to a fine powder in
liquid nitrogen. The sample was dissolved in extraction buffer (2
ml/g) (50 mM Tris-HCl [pH 7.5], 10 mM EDTA, 150 mM NaCl, 50 mM
NaF, 500 nM microcystin, 1:30 dilution of protease inhibitor cocktail
for plant cells [Sigma], 10% glycerol, and 0.5% Triton X-100) and
then spun at 5,000 × g for 10 min at 4°C. The supernatant was
transferred into a new tube and incubated with anti-FLAG M2 affin-
ity gel (Sigma) for 3 hr at 4°C. The beads were washed three times
with extraction buffer. The immunoprecipitates were eluted with 1×
SDS buffer, separated on a 4%–20% Novex Tris-Glycine SDS-PAGE
gel (Invitrogen), transferred to a PVDF membrane (Millipore), incu-
bated with anti-FLAG (Sigma) followed by donkey anti-mouse IR-
Dye 800-conjugated secondary antibody (Rockland Immunochemi-
cals), and quantified with the Odyssey Infrared Imaging system
(LI-COR Biosciences). The 32P radioactive signal of BRI1-FLAG was
quantified with a PhosphorImager (Molecular Dynamics). The spe-
cific activity of each sample was calculated by the ratio of arbitrary
units of 32P radioactive signal to the amount of protein and was
further normalized with the mean of all six samples on the same
membrane.
Synthesis and Purification of the CT Peptide
The CT-41 and CT-25 peptides (see Figure 4A) of BRI1 were synthe-
sized with standard Fmoc chemistry on an ABI Synergy 432A pep-
tide synthesizer. The peptides were deprotected and cleaved from
the resin and then purified by ether precipitation. Analysis with
mass spectrometry (MALDI-TOF) showed the expected masses.
The CT-41 peptide was further purified by HPLC to eliminate some
shorter sequences from the preparation.
Phosphoamino Acid Analysis
The CT-41 and CT-25 peptides were phosphorylated by BRI1 ki-
nase as described above, and they were separated in and excised
from a Novex 16% Tricine SDS-PAGE gel (Invitrogen); phospho-
amino acid analysis was performed in accordance with the pro-
cedures described by Meisenhelder et al. (1999).
Phosphopeptide Mapping
Phosphopeptide mapping was conducted in accordance with the
procedures (for sample preparation) described by Meisenhelder et
al. (1999). The final tryptic digests were loaded onto the TLC plates
and separated by electrophoresis at (pH 1.9) for 30 min at 1 kV in
the first dimension; the second dimension was achieved by as-
cending chromatogram with phosphochromo buffer for 16–18 hr.
Coimmunoprecipitation of BRI1-CFP and BRI1-FLAG
Total protein was extracted from transgenic det2-1 plants contain-
ing BRI1-CFP and BRI1-FLAG and from transgenic Col-0 contain-
ing BRI1-GFP alone. Short-day grown seedlings were treated with
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864H2O or 1 M of BL for 1 hr, ground to fine powder in liquid nitrogen, F
band solubilized with 2× extraction buffer (100 mM Tris-HCl [pH 7.5],
300 mM NaCl, 2 mM EDTA, 10% glycerol, and 1:100 of protease inhibi- H
tor cocktail [Sigma]). The extracts were centrifuged at 5,000 × g for 10 G
min, and the resultant supernatant was transferred to a new tube p
and centrifuged again at 5,000 × g for 5 min. The supernatant was i
filtered through two layers of miracloth (CalBiochem) and was spun
H
at 100,000 × g for 90 min at 4°C to obtain the total microsomal
C
fraction. The pellet was resuspended in membrane solubilization
w
buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 10%
s
glycerol, 0.2% Triton X-100, and 1:100 protease inhibitor cocktail)
2
to release membrane proteins. The solution was spun again at
H100,000 × g for 60 min at 4°C, and the supernatant was used for
nimmunoprecipitation. The immunoprecipitation was performed by
Hincubating the supernatant with prewashed anti-FLAG M2 affinity
sgel (Sigma) for 3 hr, which was followed by washing in the same
buffer four times. For the BL-treated samples, 1 M of BL was H
present in the extraction and solubilization buffers. The immuno- r
precipitates were eluted with 1.5 × SDS sample buffer by boiling
H
for 5 min. Either total membrane or immunoprecipitated proteins
Hwere separated on a 4%–20% Novex Tris-Glycine SDS-PAGE gel
pand transferred to nitrocellulose membrane for immunoblot analy-
Ksis with monoclonal anti-FLAG M2 (Sigma) or polyclonal anti-GFP
o(Molecular Probes) antibodies.
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